News

Bio-Rad raises 2025 life science guidance to flat to 1% growth and expands ddPCR portfolio following Stilla acquisition
Rad's Q2 2025 earnings insights, including raised guidance, Life Sciences growth, ddPCR expansion, and strategic acquisitions.
Repligen Announces Strategic Partnership with Novasign to Further Advance Bioprocessing Digitalization
Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced Novasign and Repligen have entered into a strategic partnership to develop ...